KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosCalibração aproximadaProbabilidade implícita atualBefore Jul 1, 2027 50%-1.0%Líder entre 5 opções
Qualidade do mercado
52 / 100
Qualidade médiaVolume 24h
279,6 €
Liquidez
11,6 mil €
Liquidez médiaCompra / Venda
46.0% / 50.0%
Spread
8.7%
Spread amploDados do mercado
Atualizado há 20 minutos
14/05/26, 2:001/07/27, 3:59
Tendências
Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro
Resultado escolhido
Before Jul 1, 202750%
Tendência de volume
$3182 de jul.25d de dados26 de jul.
Mercados Relacionados
New pandemic in 2026?
6,2 mil €Sim: 7%
POLYMARKET
POLYMARKET
Measles cases in 2026?
2,5 mil €Above 4000: 39%KALSHI
KALSHI
Hantavirus pandemic in 2026?
2,2 mil €Sim: 3%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
1,7 mil €Sim: 4%POLYMARKET
POLYMARKET
When will the FDA reclassify BPC-157 to Category 1?
1,3 mil €Before September: 24%KALSHI
KALSHI
When "Will Masking Return"? (widespread mask mandates in the USA)
996,3 €September 2023: 1%MANIFOLD MARKETS
MANIFOLD MARKETSAtivos nestes tópicos
Regras
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: